Inventiva (IVA) Q2 2026 earnings summary

Executive summary

• Lanifibranor advanced through Phase III NATiV3 trial, fully enrolled with 1,009 patients, and topline results expected Q4 2026, supporting regulatory filings and commercial launch preparations.

• Lanifibranor targets both intrahepatic and extrahepatic disease drivers, aiming for a differentiated, once-daily oral therapy for MASH, with broad histological improvements shown in Phase IIb.

• The addressable MASH market is projected to exceed $15 billion by 2035, with significant unmet need and rapid growth in diagnosed patient pools.

• Major financial restructuring in June 2026 included a €103 million equity offering, full repayment of EIB loans, and €75 million new debt financing.

• Leadership team and board were strengthened with new executive appointments and independent board members to support regulatory and commercial milestones.

Financial highlights

• Cash, cash equivalents, and short-term deposits totaled €233.9 million as of June 30, 2026, providing runway until end of Q2 2027, extendable to Q1 2028 with additional financing.

• R&D expenses were €46.2 million in H1 2026, up 3% year-over-year, reflecting ongoing clinical development.

• Marketing/business development expenses rose to €2.6 million, and G&A expenses increased to €22.2 million in H1 2026.

• Net loss for H1 2026 was €69.5 million, a significant improvement from €175.9 million in H1 2025, mainly due to positive fair value adjustments.

• Revenue for H1 2026 was €20,000, down from €4.5 million in H1 2025, reflecting the absence of milestone or licensing payments.

Outlook and guidance

• Cash runway extends to end of Q2 2027, with potential extension to Q1 2028 if additional financing tranches are secured.

• Preparing for NDA submission in H1 2027 and potential U.S. commercial launch in 2028, contingent on positive Phase III results.

• Confirmatory outcomes trial planned for advanced disease populations post-approval.

• Additional funding will be required for long-term objectives, including commercialization.

• Access to further tranches of debt and warrant exercises is contingent on positive Phase III results and other milestones.